Drug Trial Radar · NCT02986100
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Nov 2016
Primary completion
Dec 2017
Study completion Sep 2018
Sponsor
- Lead sponsor
- pharmaand GmbHIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered \[14C\] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation
Conditions
- Solid Tumor
Interventions
C-14 labeled RucaparibDrug
Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
RucaparibDrug
200 \& 300 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics of 14C-labeled rucaparib (radioactivity in whole blood and plasma): tmaxTime frame: Days 1-13
- Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CmaxTime frame: Days 1-13
- Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): t1/2Time frame: Days 1-13
- Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): AUCTime frame: Days 1-13
- Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CL/FTime frame: Days 1-13
- Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): V/FTime frame: Days 1-13
- Excretion rate of 14C-labeled rucaparib(radioactivity in feces)Time frame: Days 1-13
- Excretion rate of 14C-labeled rucaparib(radioactivity in urine)Time frame: Days 1-13
- Pharmacokinetics of rucaparib (in urine): CLRTime frame: Days 1-13
- Excretion rate of 14C-labeled rucaparib(radioactivity in vomit, if applicable)Time frame: Days 1-13
- Metabolite identification of rucaparib in plasma, urine and fecesTime frame: Days 1-13
- Cumulative whole blood:plasma ratio calculated for CmaxTime frame: Days 1-13
- Cumulative whole blood:plasma ratio calculated for AUC0-tlastTime frame: Day 1-13
- Cumulative whole blood:plasma ratio calculated for AUCinfTime frame: Day 1-13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Magyarország Kft.
Budapest, Rottenbiller Utca 13, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.